RT Journal Article
SR Electronic
T1 Evaluation of a Rapid and Accessible RT-qPCR Approach for SARS-CoV-2 Variant of Concern Identification
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.02.07.22270629
DO 10.1101/2022.02.07.22270629
A1 Yeung, Priscilla S.-W.
A1 Wang, Hannah
A1 Sibai, Mamdouh
A1 Solis, Daniel
A1 Yamamoto, Fumiko
A1 Iwai, Naomi
A1 Jiang, Becky
A1 Hammond, Nathan
A1 Truong, Bernadette
A1 Bihon, Selamawit
A1 Santos, Suzette
A1 Mar, Marilyn
A1 Mai, Claire
A1 Mfuh, Kenji O.
A1 Miller, Jacob A.
A1 Huang, ChunHong
A1 Sahoo, Malaya K.
A1 Zehnder, James L.
A1 Pinsky, Benjamin A.
YR 2022
UL http://medrxiv.org/content/early/2022/02/08/2022.02.07.22270629.abstract
AB The ability to distinguish between SARS-CoV-2 variants of concern (VOCs) is of ongoing interest due to differences in transmissibility, response to vaccination, clinical prognosis, and therapy. Although detailed genetic characterization requires whole-genome sequencing (WGS), targeted nucleic acid amplification tests can serve a complementary role in clinical settings, as they are more rapid and accessible than sequencing in most laboratories.We designed and analytically validated a two-reaction multiplex reverse transcription quantitative PCR (RT-qPCR) assay targeting spike protein mutations L452R, E484K, and N501Y in Reaction 1, and del69-70, K417N, and T478K in Reaction 2. This assay had 95-100% agreement with WGS in 502 upper respiratory swabs collected between April 26 and August 1, 2021, consisting of 43 Alpha, 2 Beta, 20 Gamma, 378 Delta, and 59 non-VOC infections. Validation in a separate group of 230 WGS-confirmed Omicron variant samples collected in December 2021 and January 2022 demonstrated 100% agreement.This RT-qPCR-based approach can be implemented in clinical laboratories already performing SARS-CoV-2 nucleic acid amplification tests to assist in local epidemiological surveillance and clinical decision-making.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study did not receive any fundingAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was conducted with Stanford institutional review board approval (protocol 57519), and individual consent was waived.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors